Business Context and Reporting Period
This Form 8-K is filed by N2OFF, Inc. (trading symbol: NITO) on May 22, 2025, reporting events occurring between May 18, 2025, and May 22, 2025. The Company is an emerging growth company incorporated in Nevada with principal executive offices in Israel. The filing primarily concerns the acquisition of MitoCareX Bio Ltd. and related financing arrangements.
Key Financial Metrics and Agreements
The filing does not provide consolidated revenue, profit, cash flow, or margin data for the reporting period. Key financial instruments disclosed include:
- Third Loan Agreement: N2OFF provided a new loan of $250,000 to MitoCareX on May 22, 2025.
- Interest Rate: Accrues at the annual rate per the Israel Tax Authority for USD loans (USD exchange rate fluctuation plus 3%).
- Loan Term: Six months, with repayment due at maturity.
- Guarantee: Repayment is guaranteed by L.I.A. Pure Capital Ltd.
- Previous Loans: Two prior loans of $250,000 each (dated Dec 22, 2024, and Mar 12, 2025) were amended to extend their terms by 180 days.
Material Changes and Agreements
The filing details significant amendments to the acquisition strategy for MitoCareX:
- Acquisition Agreement Amendment: On May 18, 2025, the exclusivity period for the acquisition of MitoCareX was extended by 90 days. The total window for closing is now 180 days from the original agreement date. If closing does not occur within this period, either party may terminate the agreement.
- Loan Extensions: On May 22, 2025, the terms of the First and Second Loan Agreements were extended by 180 days to support MitoCareX's ongoing costs until the acquisition closes.
- Repayment Condition: In the event MitoCareX becomes a subsidiary of N2OFF, any outstanding loan amounts will be deducted from future allocations to MitoCareX during the first year post-transaction.
Outlook, Risks, and Management Commentary
Management commentary is limited to the operational necessity of the loans to assist MitoCareX with financing ongoing costs until the closing of the acquisition. The filing highlights the following risks and contingencies:
- Closing Risk: The acquisition is contingent on closing within the extended 180-day window; failure to close allows for termination by either party.
- Financial Contingency: The repayment of the $250,000 loans is contingent on the transaction status, with potential deduction from future capital allocations if the acquisition succeeds.
- Interest Rate Fluctuation: The interest rate on the loans is variable, tied to USD exchange rate fluctuations plus a fixed percentage.
Investor Verification Checklist
- Verify the exact original date of the Securities Purchase and Exchange Agreement to calculate the precise 180-day termination deadline.
- Confirm the current status of MitoCareX's operations and whether the extended exclusivity period is sufficient for closing.
- Review the full text of the Loan Amendments (Exhibits 10.3 and 10.4) for any covenants or default triggers not summarized in the 8-K.
- Assess the financial health of L.I.A. Pure Capital Ltd. as the guarantor of the $250,000 loan.
- Monitor for subsequent filings regarding the final closing of the MitoCareX acquisition or a termination notice.